News

EY-Parthenon, Microsoft Report Highlights AI’s Role in Drug Discovery, Clinical Trials, and Manufacturing

A new report by EY-Parthenon and Microsoft, “Artificial Intelligence at the Helm: Revolutionizing the Life Sciences Sector”, released at BioAsia 2025, provides a strategic roadmap for pharma organizations to scale AI effectively.

• By Pooja Chaturvedi Sah
• New Delhi
• Feb 25, 2025

News

Artificial intelligence (AI) is rapidly reshaping the pharmaceutical and life sciences sector, driving efficiencies in drug discovery, clinical trials, manufacturing, and regulatory compliance. However, while AI adoption is growing, widespread implementation remains a challenge. 

A new report by EY-Parthenon and Microsoft, “Artificial Intelligence at the Helm: Revolutionizing the Life Sciences Sector”, released at BioAsia 2025, provides a strategic roadmap for pharma organizations to scale AI effectively. 

The report identifies AI adoption challenges, industry-wide trends, and key strategies to accelerate AI integration across the pharma value chain. 

AI Adoption in Pharma: The Maturity Framework 

The report introduces an AI Maturity Framework, categorizing pharma organizations into different stages based on their level of AI integration: 

• Basic Stage: Companies experimenting with AI but lacking large-scale implementation. 

• Intermediate Stage: Organizations integrating AI into select functions but not yet optimizing it fully. 

• Advanced Stage: Enterprises leveraging AI across operations to drive competitive differentiation. 

• Mixed Maturity Levels: Some organizations operate at different AI maturity levels across various functions, reflecting diverse adoption rates in the industry. 

Suresh Subramanian, National Lifesciences Leader, EY-Parthenon India, emphasized the fundamental shift AI is bringing to the industry. “AI is no longer a futuristic concept. It is fundamentally reshaping the life sciences sector. From accelerating drug discovery to optimizing clinical trials and revolutionizing manufacturing, AI is driving efficiencies across the entire pharma value chain. However, successful adoption requires more than just experimentation. Our AI Maturity Framework provides a structured roadmap to help organizations move from fragmented AI initiatives to enterprise-wide transformation. Organizations that proactively invest in AI maturity today will be the industry leaders of tomorrow.” 

Challenges Hindering AI Adoption in Pharma

Despite AI’s potential to revolutionize the pharma industry, the report highlights three major barriers to widespread adoption: 

1. Ethical Challenges • AI-driven decision-making raises concerns about algorithmic bias, potentially leading to inequitable treatment protocols. • Lack of transparency in AI models makes it difficult to interpret and validate clinical recommendations. 

2. Technical Barriers • AI adoption requires high-quality, structured data, but pharma companies struggle with data privacy, security, and regulatory compliance. • Navigating evolving regulations is a significant hurdle for AI integration in clinical trials and drug approvals. 

3. Operational Roadblocks • Shortage of AI-skilled professionals limits the ability of companies to implement AI at scale. • Resistance to change within organizations slows down AI adoption, requiring leadership-driven transformation strategies. 

“AI is automating repetitive tasks and bringing operational efficiencies across all roles. As AI automates these tasks, professionals must shift toward more strategic, AI-augmented roles,” the report stated. 

AI’s Expanding Role in Pharma and Life Sciences 

AI is playing a transformative role across multiple functions in the life sciences industry, including: 

1. Pharmaceuticals & Biotechnology • AI is accelerating R&D by identifying drug targets, predicting molecular interactions, and enhancing toxicity assessments. • In clinical trials, AI is optimizing patient recruitment, trial planning, and data analysis, leading to faster drug development. 

2. Manufacturing & Supply Chain • AI-driven predictive maintenance is improving production quality and minimizing equipment downtime. • Machine learning models are optimizing supply chain logistics, ensuring efficiency and cost reduction. 

3. Medical Technology • AI is revolutionizing medical device design, leveraging real-world data for more efficient prototypes. • Predictive maintenance of medical devices is reducing downtime and extending product lifespans. 

4. Academic Medical Centers & Research • AI is enhancing medical education through immersive, mixed-reality training. • AI-driven data analytics is automating literature reviews and optimizing grant funding allocation for research projects. 

Trupen Modi, Senior Industry Executive, Pharma and Life Sciences, Microsoft, highlighted how AI is transforming regulatory processes. “Advances in AI are optimizing manufacturing and supply chain processes, ensuring efficiency and reliability. AI is also reshaping the regulatory landscape by automating document analysis, streamlining submissions for regulatory approval, and monitoring compliance. This reduces time to market and improves accuracy.” 

Strategic Pillars for Successful AI Integration 

The report outlines five critical pillars that pharma organizations must focus on to successfully implement AI: 

1. AI-First Business and Operating Models – Embedding AI-driven decision-making across functions. 

2. Technology Stack Enhancements – Investing in infrastructure for large-scale AI deployment and innovation. 

3. Comprehensive AI-Ready Data Strategies – Ensuring security, compliance, and accuracy in AI-driven processes. 

4. Workforce Readiness for AI – Addressing change management and developing interdisciplinary AI skills. 

5. Risk & Compliance Frameworks – Strengthening AI governance, transparency, and cybersecurity. 

The Future of AI in Pharma: Growth and Market Projections 

The AI market in pharmaceuticals is projected to reach $16.49 billion by 2034, while AI-driven medical devices are expected to grow to $97.07 billion by 2028, the report noted. However, despite this rapid growth, pharma companies still face significant challenges in scaling AI initiatives across their entire operations. 

Experts believe that companies investing in AI maturity and strategic adoption today will gain a significant competitive edge in the global pharmaceutical market. As AI continues to reshape pharma and life sciences, the report underscores that organizations must move beyond fragmented AI initiatives toward enterprise-wide transformation. Those that proactively embrace AI will lead innovation in drug discovery, clinical trials, manufacturing, and healthcare delivery in the years to come, suggests the report.